Wu Lin, Ph.D. (he/him/his)

Quotient Sciences, United Kingdom

Poster(s):

• (T1530-03-21) A First-in-Human Assessment for TQS-168, Including Safety, Tolerability, Pharmacokinetics, Formulation Selection, and Food Effect in Healthy Volunteers
  Tuesday, October 24, 2023

  3:30 PM – 4:30 PM ET

• (W0930-12-79) Development of an Extended Release Nafamostat Formulation for Prescription Drug Overdose Protection
  Wednesday, October 25, 2023

  9:30 AM – 10:30 AM ET

• (T1430-11-71) Development of Hydrogel Polymer-Based Bilayer Gastro-Retentive Modified-Release Tablets
  Tuesday, October 24, 2023

  2:30 PM – 3:30 PM ET

• (W1030-01-06) Felodipine Solubility Enhancement via Polymeric-Lipid Extrusion 3D Printing; Development and Stability
  Wednesday, October 25, 2023

  10:30 AM – 11:30 AM ET

• (M0930-11-73) Formulation Optimization of EVX-101, a Novel Gastro-Retentive Prolonged-Release 5-HTP/Low-Dose Carbidopa Tablet
  Monday, October 23, 2023

  9:30 AM – 10:30 AM ET